Teva (TEVA) Stock Forecast for 2024–2028. Sell or Buy Prediction

Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Teva (TEVA) Stock Forecast for 2024–2028. Sell or Buy?

Updated: June 23, 2024 (07:08)

Sector: Healthcare

The share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now

Latest session on the 21st of June for
Teva Pharmaceutical Industries Lim. (TEVA) is negative
Trading Volume: 7845159
Open: 17.01 /  High: 17.105 /  Low: 16.83
What analysts predict: $18.5
52-week High/Low: $17.69 / $7.42

50/200 Day Moving Average: $15.47 / $12.11

This figure corresponds to the Average Price over the previous 50/200 days. For Teva stocks, the 50-day moving average is the support level today.

For Teva stocks, the 200-day moving average is the support level today.

Are you interested in Teva Pharmaceutical Industries Lim. (TEVA) stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Teva stock price in 2024, 2025, 2026, 2027, 2028. How much will one Teva share be worth in 2024 - 2028?

When should I take profit in Teva stock? When should I record a loss on Teva stock? What are analysts' forecasts for Teva stock? What is the future of Teva stock? We forecast Teva stock performance using neural networks based on historical data on Teva stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Teva stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Teva shares. This happens once a day.

Historical and forecast chart of Teva stock

The chart below shows the historical price of Teva stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.

Long-term forecasts by years.

Unlocking Future Profits: TEVA's Stock Set for Success?

Trend: Bullish
Jun 07, 2024

As we dive into the complexities of the pharmaceutical industry, TEVA Pharmaceuticals appears to be at a pivotal point that could significantly influence its stock rates. Analysts and prospective investors are keenly observing a series of upcoming events and factors that could serve as a beacon for forecasting TEVA's financial future. At the forefront are regulatory approvals for experimental drugs, such as Selarsdi and the encouraging clinical results for TEV-'749. These approvals are critical milestones that not only highlight the innovative prowess of TEVA but could also ensure a robust revenue stream down the line, making TEVA stock forecast a topic of heightened interest.

Keys to Predicting TEVA's Market Moves

Further fueling the optimism are the increased sales of Austedo/Austedo XR, driven by burgeoning demand in the tardive dyskinesia therapeutics market, and the company's strategic expansion into generics and biosimilars with products like Uzedy and Simlandi. These aspects contribute to a growing consensus that TEVA is a good stock to buy. Moreover, analysts are closely watching TEVA's efforts in debt reduction and its position strengthening after achieving national opioid settlements, alongside the performance of its pipeline of experimental medications targeting a broad spectrum of diseases. These elements form the bedrock for analysts to make the most accurate TEVA stock price predictions.

To navigate the volatile waters of stock investments, considering factors such as competition in key markets and the outcomes of clinical trials for drugs like TEV-'574 and TEV-'286 becomes crucial. Predicting the TEVA stock buy or sell dilemma hinges on a comprehensive analysis of these intertwined factors, setting the stage for TEVA's stock price target to potentially soar. In summary, the intricate dance between regulatory approvals, market expansion, debt management, and a promising drug pipeline positions TEVA as an enticing prospect for those wondering, "Is TEVA a good stock to buy?"

Review the original Analysis
About author

Unlocking TEVA's Stock Potential: Insights into 2024's Bright Forecast

Trend: Bullish
May 09, 2024

As forecasters eye TEVA Pharmaceutical's horizon, several pivotal events and factors stand out, poised to significantly shift the company's stock trajectory. At the forefront is TEVA's recently unveiled Q1 2024 earnings results, which illuminate a path towards sustainable growth, backed by strong performance metrics. Coupled with a robust business outlook for 2024, including an adjusted EBITDA forecast up to $5.0 billion, investor optimism is hitting new highs, making the TEVA stock forecast a hot topic among market analysts.

Driving Forces Behind TEVA's Stock Surge

Analysts sharpening their pencils on TEVA's stock price predictions are paying close attention to a few critical influencers. High on the list are potential blockbuster drugs emerging from TEVA's pipeline, like TEV-749 for schizophrenia, expected to revolutionize market dynamics and cement TEVA's competitive edge. Furthermore, the strategic launch of biosimilars and direct-to-consumer (D2C) campaigns are set to catapult TEVA into new revenues realms, marking it as a TEVA stock buy or sell tipping point.

Equally significant, the company's commitment to paring down debt levels and presenting an improved net debt/EBITDA ratio is reassuring investors, nudging the TEVA stock price prediction further into positive territory. Analysts employing a holistic view, considering these catalysts alongside TEVA's quant rating—which factors in valuation, profitability, and momentum—are well-equipped to craft the most accurate TEVA stock forecast. In the dynamic world of pharmaceuticals, identifying which factors, from blockbuster drugs to financial health, will turn the tide, could indeed make TEVA a good stock to buy, promising a future as bright as its pipeline.

Review the original Analysis
About author

Unlocking Teva's Stock Future: A Guide to Predicting TEVA's Market Movement

Trend: Bullish
Mar 25, 2024

Investors and stock analysts alike are keenly observing Teva Pharmaceutical Industries, as a blend of pivotal factors could significantly sway TEVA stock forecasts. Notably, the execution of a strategic turnaround plan under new leadership is at the forefront, aimed at propelling the company into a story of growth and profitability. This plan is critical for driving sustainable growth and diversification, potentially making TEVA stock a compelling buy for investors tuned into the pharmaceutical sector's dynamic landscape.

Key Indicators for TEVA's Stock Trajectory

Delving deeper, several aspects are positioned to be game-changers for predicting TEVA's stock price movements accurately:

  • Financial Performance: TEVA's journey towards bolstering its financial health, marked by rising gross and operating margins alongside positive revenue growth, is essential. Analysts contemplating the TEVA stock price target will closely monitor these indicators for signs of enduring profitability.
  • Debt Reduction Efforts: With an emphasis on solid free cash flow and dedicated deleveraging, TEVA seeks to diminish its debt overhang. A decline in debt levels could significantly enhance TEVA's stock price prediction, signaling stability and financial discipline.
  • Reputation and Ethical Practices: Overcoming past controversies through stringent ethical standards could rejuvenate TEVA's public image. For those debating whether TEVA stock is a good buy, the company's commitment to rectifying previous missteps could be a determinant factor.

By synthesizing these elements, analysts can craft informed TEVA stock forecasts, distinguishing TEVA as either an attractive investment or a sell. Given the TEVA name's stock forecast intricacies, investors are encouraged to weigh these decisive factors carefully, potentially unlocking lucrative opportunities in a volatile market landscape.

Review the original Analysis
About author

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.

Teva daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 25 16.66 16.07 17.22 7.15
Jun 26 16.44 15.88 17.18 8.20
Jun 27 16.36 15.68 16.59 5.82
Jun 28 15.43 14.97 16.07 7.36
Jun 29 15.04 14.52 15.40 6.09
Jun 30 15.42 15.03 15.86 5.54
Jul 01 15.00 14.35 15.70 9.41
Jul 02 14.70 14.02 15.21 8.49
Jul 03 14.68 14.33 15.38 7.32
Jul 04 14.57 14.40 15.20 5.59
Jul 05 14.55 14.29 15.10 5.68
Jul 06 14.20 13.91 14.66 5.39
Jul 07 14.77 14.54 15.19 4.45
Jul 08 15.06 14.67 15.25 3.94
Jul 09 15.38 15.13 15.98 5.61
Jul 10 15.08 14.80 15.81 6.79
Jul 11 14.99 14.54 15.50 6.56
Jul 12 15.43 15.01 16.07 7.10
Jul 13 15.36 15.07 15.78 4.77
Jul 14 15.63 15.01 15.85 5.62
Jul 15 15.84 15.53 16.34 5.20
Jul 16 14.91 14.38 15.52 7.90
Jul 17 14.63 14.23 15.16 6.54
Jul 18 14.78 14.19 15.09 6.38
Jul 19 14.57 14.00 14.94 6.68
Jul 20 14.50 13.80 15.04 8.95
Jul 21 14.82 14.27 15.20 6.48
Jul 22 14.52 14.15 15.09 6.71
Jul 23 13.84 13.37 14.33 7.21
Jul 24 14.11 13.88 14.69 5.86

Teva Daily Price Targets

Teva Stock Forecast 06-25-2024.

Forecast target price for 06-25-2024: $16.66.
Negative dynamics for Teva shares will prevail with possible volatility of 6.675%.
Pessimistic target level: 16.07
Optimistic target level: 17.22

Teva Stock Forecast 06-26-2024.

Forecast target price for 06-26-2024: $16.44.
Negative dynamics for Teva shares will prevail with possible volatility of 7.579%.
Pessimistic target level: 15.88
Optimistic target level: 17.18

Teva Stock Forecast 06-27-2024.

Forecast target price for 06-27-2024: $16.36.
Negative dynamics for Teva shares will prevail with possible volatility of 5.504%.
Pessimistic target level: 15.68
Optimistic target level: 16.59

Teva Stock Forecast 06-28-2024.

Forecast target price for 06-28-2024: $15.43.
Negative dynamics for Teva shares will prevail with possible volatility of 6.857%.
Pessimistic target level: 14.97
Optimistic target level: 16.07

Teva Stock Forecast 06-29-2024.

Forecast target price for 06-29-2024: $15.04.
Negative dynamics for Teva shares will prevail with possible volatility of 5.742%.
Pessimistic target level: 14.52
Optimistic target level: 15.40

Teva Stock Forecast 06-30-2024.

Forecast target price for 06-30-2024: $15.42.
Positive dynamics for Teva shares will prevail with possible volatility of 5.249%.
Pessimistic target level: 15.03
Optimistic target level: 15.86

TEVA (TEVA) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jul. 17.42 16.28 19.46 16.33
Aug. 18.45 17.01 20.31 16.28
Sep. 19.72 18.84 20.76 9.27
Oct. 18.43 17.54 20.49 14.39
Nov. 17.51 16.51 18.69 11.69
Dec. 17.79 16.03 18.36 12.71

Teva forecast for this year

Teva Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $17.4213. Pessimistic: $16.28. Optimistic: $19.46

Teva Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $18.4527. Pessimistic: $17.01. Optimistic: $20.31

Teva Stock Prediction for Sep 2024

An uptrend is forecast for this month with an optimal target price of $19.7222. Pessimistic: $18.84. Optimistic: $20.76

Teva Stock Prediction for Oct 2024

An downtrend is forecast for this month with an optimal target price of $18.4284. Pessimistic: $17.54. Optimistic: $20.49

Teva Stock Prediction for Nov 2024

An downtrend is forecast for this month with an optimal target price of $17.5144. Pessimistic: $16.51. Optimistic: $18.69

Teva Stock Prediction for Dec 2024

An uptrend is forecast for this month with an optimal target price of $17.7946. Pessimistic: $16.03. Optimistic: $18.36

Teva (TEVA) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 17.77 15.92 19.67 19.08
Feb 19.02 16.86 21.12 20.17
Mar 18.96 17.23 19.84 13.15
Apr 21.87 19.35 24.56 21.22
May 18.47 16.40 19.66 16.54
Jun 16.14 14.82 16.76 11.56
Jul 16.45 15.13 17.19 11.94
Aug 17.05 15.33 18.72 18.08
Sep 17.19 15.35 17.82 13.89
Oct 16.42 14.32 18.39 22.14
Nov 15.45 14.43 15.97 9.60
Dec 14.29 13.76 15.29 10.01

Teva (TEVA) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 13.58 11.91 14.32 16.84
Feb 12.12 11.46 12.57 8.80
Mar 11.11 10.33 12.23 15.55
Apr 11.31 10.75 12.72 15.50
May 11.76 10.43 12.59 17.19
Jun 10.91 10.44 11.77 11.28
Jul 11.11 10.36 11.87 12.73
Aug 12.56 11.52 13.23 12.92
Sep 12.00 10.56 12.90 18.16
Oct 10.20 9.04 10.98 17.68
Nov 10.96 10.42 12.37 15.74
Dec 9.96 9.58 10.46 8.38

Teva (TEVA) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 10.36 9.76 11.04 11.56
Feb 11.92 10.62 13.14 19.16
Mar 12.95 11.54 14.32 19.39
Apr 12.83 12.25 14.34 14.59
May 14.39 13.30 15.40 13.60
Jun 14.39 13.72 14.94 8.17
Jul 14.13 12.39 14.97 17.22
Aug 13.79 12.20 14.32 14.79
Sep 13.31 11.71 14.95 21.65
Oct 11.69 11.17 12.62 11.56
Nov 10.40 9.17 11.70 21.62
Dec 11.16 10.18 11.66 12.71

Teva (TEVA) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 12.02 11.00 13.23 16.86
Feb 12.91 12.04 14.12 14.77
Mar 13.38 12.03 14.41 16.49
Apr 12.48 11.76 12.96 9.25
May 14.04 12.96 15.28 15.15
Jun 15.39 13.52 15.90 15.02
Jul 16.94 15.34 19.05 19.49
Aug 15.75 14.69 16.63 11.67
Sep 17.91 16.74 19.80 15.48
Oct 15.68 14.20 17.13 17.13
Nov 14.85 13.19 16.51 20.14
Dec 15.68 13.75 17.59 21.83

Teva information and performance

Teva Address


Market Capitalization: 19 255 402 000 $

Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.

EBITDA: 4 462 000 000 $

EBITDA of Teva is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.843

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -0.42

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.4
Quarterly Revenue Growth YOY: 0.043
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 5.59

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.05

Enterprise Value (EV) /Revenue

EV To EBITDA: 20.84

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 1132640000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Teva (TEVA) stock dividend

Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.